↓ Skip to main content

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

Overview of attention for article published in Frontiers in Aging Neuroscience, March 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 X user

Readers on

mendeley
146 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
Published in
Frontiers in Aging Neuroscience, March 2014
DOI 10.3389/fnagi.2014.00053
Pubmed ID
Authors

Lucilla Parnetti, Lucia Farotti, Paolo Eusebi, Davide Chiasserini, Claudia De Carlo, David Giannandrea, Nicola Salvadori, Viviana Lisetti, Nicola Tambasco, Aroldo Rossi, Nour K. Majbour, Omar El-Agnaf, Paolo Calabresi

Abstract

There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis. Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer's disease (AD) biomarkers-β-amyloid 1-42 (Aβ42), total tau (t-tau), phosphorylated tau (p-tau)-differentiate PD patients from controls, and that reduced levels of Aβ42 represent a predictive factor for development of cognitive deterioration in PD. In this prospective study carried out in 44 PD patients and 25 neurological controls we wanted to verify whether the combination of CSF α-synuclein species-t-α-syn and o-α-syn-and classical AD biomarkers may help in differentiating PD from neurological controls, and if these biomarkers may predict cognitive decline. The median of follow-up duration was 3 years (range: 2-6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used for monitoring cognitive changes along time, being administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic value, significantly contributing to the discrimination of PD from neurological controls. A greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ42/tau ratios (Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR = 12.52). Low CSF Aβ42 level was associated with a higher rate of MMSE and MoCA decline, confirming its role as independent predictive factor for cognitive decline in PD. None of the other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic value. We conclude that combination of CSF o/t-α-syn and Aβ42/tau ratios improve the diagnostic accuracy of PD. PD patients showing low CSF Aβ42 levels at baseline are more prone to develop cognitive decline.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 146 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Netherlands 1 <1%
United States 1 <1%
Canada 1 <1%
Unknown 142 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 24 16%
Student > Ph. D. Student 23 16%
Student > Master 16 11%
Student > Bachelor 13 9%
Student > Doctoral Student 10 7%
Other 33 23%
Unknown 27 18%
Readers by discipline Count As %
Neuroscience 31 21%
Medicine and Dentistry 28 19%
Biochemistry, Genetics and Molecular Biology 13 9%
Agricultural and Biological Sciences 11 8%
Psychology 9 6%
Other 15 10%
Unknown 39 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2014.
All research outputs
#15,299,919
of 22,754,104 outputs
Outputs from Frontiers in Aging Neuroscience
#3,577
of 4,747 outputs
Outputs of similar age
#133,040
of 226,159 outputs
Outputs of similar age from Frontiers in Aging Neuroscience
#37
of 51 outputs
Altmetric has tracked 22,754,104 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,747 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.1. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,159 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.